Husseini K. Manji, M.D., F.R.C.P.C., is Co-Chair of the UK Government's Mental Health Goals Program and Professor at the University of Oxford, as well as Adjunct Professor at Yale University and Visiting Professor at Duke University.

Dr. Manji previously served as Global Neuroscience R&D Head at Johnson & Johnson, where he oversaw the discovery, development, and/or launch of several transformative treatments for serious neuropsychiatric and neurodegenerative disorders. He helped pioneer the first novel antidepressant mechanism in more than sixty years and led the work behind the first-ever neuroscience medication to receive FDA Breakthrough Therapy designation. His pipeline/portfolio also advanced several novel MOA treatments for neuropsychiatric/ neurodegenerative disorders. Before entering industry, he was Chief of the Laboratory of Molecular Pathophysiology and Director of the Mood and Anxiety Disorders Program at the U.S. National Institutes of Health, then the largest program of its kind in the world.

His research centers on disease- and treatment-induced changes in synaptic and neural plasticity in severe neuropsychiatric disorders, with sustained emphasis on translational science and biomarker/ treatment development.

Elected to the U.S. National Academy of Medicine, Dr. Manji has chaired/served on the World Dementia Council, the WEF Global Future Councils, NIH Novel/Exceptional Technology and Research Advisory Committee, & NAM Neuroscience/ Behavior/ Brain Function/ Disorders. He serves on the several Boards/SABs including Harvard University/McLean Hospital, and the Dana Foundation. His several honors include the National Academy of Medicine International Mental Health Prize, the NIMH Director's Career Award, and the PhRMA Research & Hope Award, He has authored more than 350 publications.

Product: VAFSEO® (vadadustat)

Company: Akebia Therapeutics

About the Product:

Product: TRYPTYR® (acoltremon ophthalmic solution)

Company: Alcon

About the Product:

TRYPTYR is the first topical ocular pharmaceutical neuromodulator that leverages the eye's natural mechanism for regulating tear production to replenish basal tears. It stimulates TRPM8 receptors, activating the trigeminal nerve to coordinate secretion from the lacrimal glands, meibomian glands, and goblet cells to replenish the body’s natural tears. Unlike traditional Dry Eye Disease treatments that primarily supplement tears or target inflammation, TRYPTYR increases the neurosensory drive to produce basal tears and has been shown to increase natural tear production as early as Day 1. This innovative approach offers patients and clinicians a faster, evidence-based option for managing Dry Eye Disease.

Product: HERNEXEOS® (zongertinib tablets)

Company: Boehringer Ingelheim

About the Product:

HERNEXEOS® (zongertinib tablets) is an irreversible tyrosine kinase inhibitor (TKI) that selectively inhibits HER2 (ERBB2) and the first orally administered, targeted therapy for adult patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer. With HERNEXEOS, Boehringer Ingelheim is delivering on the promise to transform care for people with this rare and aggressive cancer. HERNEXEOS is also being evaluated across a range of earlier stages and advanced solid tumors with HER2 alterations. Boehringer has a clear aspiration - to transform the lives of people facing cancer by delivering unprecedented impact, with the ultimate goal to redefine standards of care.

Product: NUZOLVENCE^® - XACDURO^®  -ZEVTERA^®

Company: Innoviva Specialty Therapeutics, Inc.

About the Products:

NUZOLVENCE (zoliflodacin) for the treatment of uncomplicated urogenital gonorrhea due to Neisseria gonorrhoeae in adults and pediatric patients 12 years of age and older, weighing at least 35 kg represents the convergence of scientific innovation, public health purpose, and global awareness. It delivers the first new antibacterial class for gonorrhea in decades while transforming treatment through a simple, single-dose oral regimen that expands scalable access. Equally important, it demonstrates that a deliberately structured public–private partnership can overcome longstanding economic barriers to antibiotic development and deliver meaningful innovation where it is most needed. In doing so, NUZOLVENCE not only advances the standard of care for a highly resistant and globally prevalent pathogen but also establishes a model for future antimicrobial innovation—one that aligns scientific excellence with societal impact.

XACDURO is the first pathogen-targeted antibacterial developed and approved to treat hospital acquired and ventilator-associated pneumonia caused by Acinetobacter baumannii. Previously, there was no clear standard of care antibiotic regimen for Acinetobacter infections resulting in a mortality rate ranging from 30-70%. The approval of XACDURO addresses a global public health threat and delivers a safe and effective treatment option for patients suffering from these serious and life-threatening infections.

ZEVTERA is an advanced-generation cephalosporin antibiotic uniquely developed to treat resistant bacterial infections especially methicillin resistant staphylococcus aureus (MRSA) bacteremia. The innovative and tenacious global development program spanned several companies and culminated in FDA approval for the treatment of adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including right-sided infective endocarditis. The approval for this life-threatening indication represented the first for an antibiotic in almost 20 years.

Product: ICOTYDE™

Company: Johnson & Johnson

About the Product:

Icotrokinra (ICOTYDE™) is a first-in-class, targeted oral peptide that precisely blocks the IL-23 receptor and inhibits IL-23-driven inflammatory signaling. Icotrokinra is approved for moderate-to-severe plaque psoriasis in patients aged ≥12 years (≥40 kg) eligible for systemic therapy or phototherapy. Icotrokinra has demonstrated high, durable efficacy and favorable safety in the simplicity of a once-daily pill, which, together with no routine monitoring or latent tuberculosis infection screening requirements, may support earlier intervention and sustained adherence, ultimately improving outcomes. Ongoing Phase 3 studies in psoriatic arthritis and inflammatory bowel disease may establish icotrokinra as a transformational treatment across multiple immune-mediated diseases.

Product: SPRAVATO® Nasal Spray

Company: Johnson & Johnson Innovative Medicine

About the Product:
SPRAVATO® (esketamine) CIII Nasal Spray, developed by Johnson & Johnson, represents one of the most significant advances in depression treatment in more than 50 years. Targeting the glutamatergic system through NMDA receptor antagonism, SPRAVATO offers rapid antidepressant effects through an intranasal, supervised outpatient model for treatment-resistant depression and major depressive disorder with acute suicidal ideation or behavior. The innovation extends beyond the molecule to include a drug-device combination and differentiated treatment paradigm designed for rapid symptom relief and durable benefit. In 2025, SPRAVATO became the first and only FDA-approved monotherapy for adults with TRD, helping redefine expectations in depression care.

Product: VOQUEZNA®

Company: Phathom Pharmaceuticals

About the Product:

VOQUEZNA (vonoprazan) is a first-in-class potassium-competitive acid blocker (PCAB) approved in the U.S. for the treatment of gastroesophageal reflux disease (GERD) and, in combination with antibiotics, for H. pylori infection. With a novel mechanism of action, VOQUEZNA delivers rapid, potent, and durable acid suppression, with a safety profile comparable to proton pump inhibitors (PPIs). In pivotal Phase 3 trials, VOQUEZNA demonstrated key efficacy advantages over a PPI across multiple endpoints. Its approval represents the first major innovation in GERD treatment in more than 30 years, offering the potential to significantly advance care for millions of patients with acid-related disorders.

Product: CARDAMYST® (etripamil) Nasal Spray

Company: Milestone Pharmaceuticals

About the Product:

CARDAMYST® (etripamil) nasal spray is the first and only FDA-approved, self-administered treatment for the rapid conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. This novel calcium channel blocker is uniquely paired with an intranasal delivery system enabling patients to treat attacks wherever they occur. CARDAMYST provides healthcare professionals with a safe and rapid-acting treatment approach that supports a patients' ability to self-administer a treatment for this serious cardiovascular disease. Currently, etripamil is in Phase 3 development for control of acute AFib-RVR in adults. For more information, visit CARDAMYST.com.

Product: PLUVICTO^®

Company: Novartis

About the Product:

Since launch, PLUVICTO has treated more than 20,000 patients with prostate cancer, helping many live longer or delay disease progression. Following expansion into earlier settings, adoption has continued to grow, with physicians increasingly choosing PLUVICTO for eligible patients. As part of a PSMA-targeted theranostic approach, PLUVICTO delivers targeted radiation directly to cancer cells in patients identified through PSMA-specific imaging. Innovation extends beyond the molecule to specialized manufacturing, educational initiatives such as the RLT Institute, and the introduction of a pre-filled syringe format. Supported by multidisciplinary collaboration, PLUVICTO has established a strong foundation for future advances in RLT and oncology overall.

Product: SCEMBLIX^®

Company: Novartis

About the Product:

SCEMBLIX® (asciminib)—redefining what’s possible. It’s the first and only approved allosteric inhibitor of BCR::ABL1, which enables SCEMBLIX to maintain high selectivity and potency. In clinical studies, SCEMBLIX delivered fast, deep molecular responses vs standard-of-care therapies, while also demonstrating a safety and tolerability profile that offers patients an additional treatment opportunity. The FDA has also acknowledged that SCEMBLIX has the potential to advance treatment—with 3 FDA Breakthrough Therapy designations, SCEMBLIX offers patients another path forward. 

Product: TALVEY® (talquetamab-tgvs)

Company: UroGen Pharma

About the Product:

ZUSDURI® is the first and only FDA-approved non-surgical medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). [JK1.1]Combining mitomycin with UroGen's proprietary reverse thermal hydrogel (RTGel®) technology, ZUSDURI is an intravesical chemoablative therapy that provides potent tumor ablation through, prolonged drug dwell time. Unlike the traditional management of recurrent LG-IR-NMIBC, which relies on repeated transurethral resection of bladder tumors (TURBT), ZUSDURI offers a non-surgical pharmacologic treatment option that can be administered in an ambulatory setting. In the pivotal ENVISION trial, 78% of response-evaluable patients achieved a complete response, with 79% of responders remaining in complete response for at least 12 months. ZUSDURI represents an important advancement by providing an effective non-surgical treatment option for patients with recurrent LG-IR-NMIBC.